Alto Neuroscience, Inc. ANRO 深 滬
已收盤 06-18 16:00:00 美东时间
22.74
+0.950
+4.36%
華盛通- 最 高23.51
- 今 開22.50
- 成交量 55.82万股
- 最 低 21.759
- 昨 收 21.79
- 總市值 79.80万
- 52周最高 28.441
- 市盈率 靜 --
- 換手率 1590.64%
- 52周最低 2.15
- 委 比 -98.02%
- 總股本 3.51万
- 歷史最高 28.441
- 量 比 2.00
- 振 幅 8.04%
- 歷史最低 1.60
- 每 手 1
- 風險率 7.95%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股牛股 | NUVL飙升39%，获葛兰素史克高额溢价收购；Velo3D大涨近20%
NUVL飙升39%，获葛兰素史克高额溢价收购；Velo3D大涨近20%，进军燃气轮机增材制造领域；职业教育涨逾18%，收购整合完成后大幅上调营收预期>>
06-10 18:45
美股大行评级 | 花旗上调英特尔目标价至130美元；大摩上调英伟达目标价至285美元；National 、Yesway获多家大行首予买入评级
今日重点评级关注：TD Cowen：维持Strive"买入"评级，目标价从28美元升至30美元；蒙特利尔银行：维持KinderCare Learning"跑赢大市"评级，目标价从4美元升至6美元
05-19 10:55
美股大行评级 | 阿里、京东、英伟达、思科等获多家大行上调目标价；Doximity、Dynatrace、Enovix、Wix.com等遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Autolus Therapeutics"买入"评级，目标价从9美元升至10美元；Maxim Group：维持Rezolute"买入"评级，目标价从4美元升至10美元
05-15 10:49
Alto Neuroscience Q1 EPS $(0.80) Misses $(0.54) Estimate
Alto Neuroscience (NYSE:ANRO) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.54) by 48.15 percent. This is a 42.86 percent decrease over losses of $(0.56) per share from
05-13 19:25
美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
HC Wainwright & Co. Reiterates Buy on Alto Neuroscience, Maintains $50 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Alto Neuroscience (NYSE:ANRO) with a Buy and maintains $50 price target.
05-12 01:38
Alto Neuroscience Presents Data On Its Phase 2a Study Of ALTO-207 In Participants With Major Depressive Disorder At 2026 Annual Meeting Of Society Of Biological Psychiatry
Alto Neuroscience, Inc. (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced the presentation of data from a randomized, single-blind,
05-04 20:11
Alto Neuroscience Initiates Phase 2b Trial Of ALTO-207
— Phase 2b closely resembles PAX-D study design, which demonstrated an effect size for pramipexole more than two times larger than approved TRD therapies —— Trial design and MADRS primary endpoint aligned with FDA
04-21 20:09
Alto Neuroscience Files Prospectus For Resale Of 6M Shares, Company To Receive Proceeds Only From Pre-Funded Warrants
6,000,000 SharesCommon Stock Offered by the Selling StockholdersThis prospectus relates to the proposed resale from time to time of up to 6,000,000 shares, or the Shares, of our common stock, par value $0.0001 per share,
04-11 04:25
美股大行评级 | 摩根大通上调霸王茶姬至"超配"，目标价上调至16美元；康尼格拉食品遭高盛、瑞银等7家机构下调目标价
今日重点评级关注：Leerink Partners：维持Camp4 Therapeutics"跑赢大市"评级，目标价从8美元升至9美元；韦德布什：维持Arcus Biosciences"跑赢大市"评级，目标价从37美元升至41美元
04-06 16:27
